Intermediates the answer to China API dependence, says Indian export delegate

By Flora Southey contact

- Last updated on GMT

GettyImages/daboost
GettyImages/daboost

Related tags: Pharmacology, Pharmaceutical drug, Active ingredient

Revising India’s intermediates manufacturing sector will reduce its dependence on China for APIs, says Pharmexcil delegate.

Over the past two decades, India has shifted its manufacturing focus from active pharmaceutical ingredients (APIs) to finished drug formulations due to the greater profit potential in bulk drug manufacture, said Pharmaceuticals Export Promotion Council of India (Pharmexcil) delegate Ravi Uday Bhaskar.

“We are importing most APIs from China,” ​he told us at CPhI Worldwide last month. “We are dependent [on Chinese APIs] not only from the exporting point of view, but dependent in the domestic market.

“Indian companies are realising that we need to build up a strategy to reduce the import dependence of APIs, as well as intermediates and chemicals.”

Manufacturing strategy

According to Ravi Uday Bhaskar, revising India’s pharmaceutical manufacturing techniques could reduce its dependence on ingredient and finished product trade.

Specifically, he said Indian firms need to revise manufacturing techniques to make intermediates – an API starting material – in order to become global players in the pharmaceutical space.

“Once you reach that level, and you are addressing the domestic needs, you are an international player,” ​he told us.

“This is the point in time when we have to do two things: we have to reduce premiums, and go for innovation. This is the focus of the Indian industry.”

He added Pharmexcil is working with the government, trade bodies and manufacturing bodies to help move the industry in this direction.

Correction: Original article stated views from IBEF, which has now been changed to Pharmexcil. 

Related news

Show more

Related products

show more

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

SQ-USP-Brochure-Thumb-AP-CC

NEW…sugarcane derived USP Squalane from Aprinnova

APRINNOVA – A joint venture of AMYRIS and NIKKOL Group | 26-Feb-2018 | Product Brochure

To date, topical formulation chemists have been restricted to using Squalane derived from the harvesting of shark livers. Neossance Squalane USP, derived...

TCC TB – a new filler for direct compression

TCC TB – a new filler for direct compression

Jungbunzlauer | 09-Oct-2017 | Technical / White Paper

TCC TB is a tricalcium citrate tetrahydrate designed to function as a direct compression excipient. It combines exceptional compression characteristics,...

Related suppliers

Follow us

Products

View more